Can a new pill slow lung scarring? small trial holds promise for IPF patients
NCT ID NCT05621252
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times
Summary
This study tested an experimental drug called PLN-74809 in 10 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The main goal was to see if the drug could reduce collagen buildup in the lungs, measured by a special PET scan. The trial is complete, and results will show if the drug is safe and may help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.